The goal of screening and monitoring programmes is to reduce the adverse clinical consequences of diabetic ketoacidosis at diagnosis and to identify children who may benefit from disease-modifying therapies to delay or reverse progression to insulin requirement. The gene discussed is INS; the disease is diabetic ketoacidosis.